about
Molecular pathways in non-alcoholic fatty liver disease.Safety of statins: an updateStatins and their interactions with other lipid-modifying medications: safety issues in the elderlyRhabdomyolysis after midazolam administration in a cirrhotic patient treated with atorvastatin.Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.Clinical approaches to non-alcoholic fatty liver diseaseLipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.Clinical perspective: statins and the liver--harmful or helpful?Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons.Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury.Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats.Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatinHepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease.Statin use and infections in Veterans with cirrhosis.Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study.
P2860
Q33890230-194C12A4-B6B9-46E1-87A0-B3FE46BF9460Q33949312-D11DB094-D527-44F1-82BC-38D4FDFB3F90Q33949348-8D5136E9-56C8-4FF5-809D-6B39FD3E2AAEQ34047690-3F6BB2B1-E670-4C61-9A74-7DAB293DC136Q35163716-C0339FF5-1D6F-4DF8-AFBB-E4B3D4FBFA5EQ36654473-F020547F-D80D-476A-B62B-BF3E75BA94D2Q37596187-8EEC5484-D951-4CEC-8228-00CF0BA70090Q37993779-882FBCDB-87A5-4C13-AF03-1EE779D8F499Q38009719-AA215CA4-AD63-4E49-AEED-4CC60134BB21Q38074826-BB7C0421-763C-4764-8B05-80647ECA784BQ40302281-29CB3238-2834-46DA-AE00-B4712263405FQ41340082-D71450E0-E643-4EDC-AC1C-F338B52DD5ACQ41977512-32BC744C-7CAB-45AF-A920-736A41BCA609Q42160233-5AFF8BBE-1943-443C-93F1-693E05C4175EQ42963633-C1233C16-3CB2-4B28-930C-12731E9AD6F7Q44875429-FA8EA5D7-ADAC-4D5F-922C-9EC03FD9ECBFQ53081272-EE43916B-F393-4932-8995-8F19C2855500
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Use of statins in patients with liver disease.
@ast
Use of statins in patients with liver disease.
@en
Use of statins in patients with liver disease.
@nl
type
label
Use of statins in patients with liver disease.
@ast
Use of statins in patients with liver disease.
@en
Use of statins in patients with liver disease.
@nl
prefLabel
Use of statins in patients with liver disease.
@ast
Use of statins in patients with liver disease.
@en
Use of statins in patients with liver disease.
@nl
P1476
Use of statins in patients with liver disease
@en
P2093
Sweta Tandra
P2888
P304
P356
10.1007/S11936-009-0028-2
P577
2009-08-01T00:00:00Z